These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 23262060)
1. Analysis of the landscape of biologically-derived pharmaceuticals in Europe: dominant production systems, molecule types on the rise and approval trends. Kyriakopoulos S; Kontoravdi C Eur J Pharm Sci; 2013 Feb; 48(3):428-41. PubMed ID: 23262060 [TBL] [Abstract][Full Text] [Related]
2. [Current impact of natural products in the discovery of anticancer drugs]. Monneret C Ann Pharm Fr; 2010 Jul; 68(4):218-32. PubMed ID: 20637355 [TBL] [Abstract][Full Text] [Related]
3. Development of biosimilars--pharmacokinetic and pharmacodynamic considerations. Wang YM; Chow AT J Biopharm Stat; 2010 Jan; 20(1):46-61. PubMed ID: 20077248 [TBL] [Abstract][Full Text] [Related]
4. Drug discovery and natural products: end of an era or an endless frontier? Li JW; Vederas JC Science; 2009 Jul; 325(5937):161-5. PubMed ID: 19589993 [TBL] [Abstract][Full Text] [Related]
5. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules. de la Torre BG; Albericio F Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446 [TBL] [Abstract][Full Text] [Related]
6. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology]. Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629 [TBL] [Abstract][Full Text] [Related]
7. The year's new drugs & biologics 2016: Part II - Trends and highlights of an unforgettable year. Graul AI; Dulsat C; Tracy M; Cruces E Drugs Today (Barc); 2017 Feb; 53(2):117-158. PubMed ID: 28387389 [TBL] [Abstract][Full Text] [Related]
8. The year's new drugs & biologics 2016: Part I. Graul AI; Pina P; Cruces E; Stringer M Drugs Today (Barc); 2017 Jan; 53(1):27-74. PubMed ID: 28387385 [TBL] [Abstract][Full Text] [Related]
9. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. DiMasi JA Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388 [TBL] [Abstract][Full Text] [Related]
10. Future directions for peptide therapeutics development. Kaspar AA; Reichert JM Drug Discov Today; 2013 Sep; 18(17-18):807-17. PubMed ID: 23726889 [TBL] [Abstract][Full Text] [Related]
11. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors]. Jahnz-Rozyk K; Wiesik-Szewczyk E; Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192 [TBL] [Abstract][Full Text] [Related]
12. Trends in development and approval times for new therapeutics in the United States. Reichert JM Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576 [TBL] [Abstract][Full Text] [Related]
13. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. Roberts SA; Allen JD; Sigal EV Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577 [TBL] [Abstract][Full Text] [Related]
14. Clinical approval success rates for investigational cancer drugs. DiMasi JA; Reichert JM; Feldman L; Malins A Clin Pharmacol Ther; 2013 Sep; 94(3):329-35. PubMed ID: 23739536 [TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody: the corner stone of modern biotherapeutics. Xia ZN; Cai XT; Cao P Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138 [TBL] [Abstract][Full Text] [Related]
16. Recent drug approvals from the US FDA and EMEA: what the future holds. Pevarello P Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069 [TBL] [Abstract][Full Text] [Related]
17. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency]. Enzmann H; Broich K Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906 [TBL] [Abstract][Full Text] [Related]
19. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role]. Ainsworth MA Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819 [TBL] [Abstract][Full Text] [Related]
20. Trends in risks associated with new drug development: success rates for investigational drugs. DiMasi JA; Feldman L; Seckler A; Wilson A Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]